Glycostem is going to participate Innate Killer Summit 2023, taken place on 28 - 30 March 2023 in San Diego, US.
Wednesday, 29 March 2023
14:30 Panel Discussion: Optimizing Innate Therapy in the Clinic
Kai Pinkernell, CMO, Glycostem

14:30 Panel Discussion: Sharing a Vision of the Future for Commercial Scale Manufacturing of Innate Immune Cells
Volker Huppert, CDO, Glycostem

15:15 Driving GMP Readiness with Scalable Manufacturing Platforms & Second Sourcing Strategies with GMP Materials
Volker Huppert, CDO, Glycostem

17:10 From Europe to the US: Sharing an Expert’s Guide to Regulatory Success in Europe, & Differences Identified in FDA Processes
Kai Pinkernell, CMO, Glycostem

Glycostem is going to attend the 2^nd Allogeneic Cell Therapies Summit Europe in London.

31^st January, 2023

16:30 GMT Maximising the Inherent Benefits of NK Cells to Effectively Target Solid Tumours

Presented by Jan Spanholtz, Chief Scientific Officer

• Capturing the intrinsic advantages of natural killer cells to infiltrate the solid tumour microenvironment
• Reflecting on NK cells anti GvHD functions to realise their full potential in allogeneic therapies
• Unlocking off-the-shelf NKs through effective and efficient large-scale manufacturing

1^st February, 2023

12.30 GMT Optimising Manufacturing and Utilising Cryopreservation to Increase Allogeneic Product Shelf Life
Presented by Volker Huppert, Chief Development Officer

• Harnessing the potential of frozen products to reduce cost of goods and increase accessibility
• Optimising cryopreservation protocol to prevent decreases in quality, stability, and potency
• Employing frozen material to address scale and logistical challenges

Glycostem Troels Jordansen is going to participate the Advanced Therapies Week 2023 in Miami, US from 18^th to 20^th Jan 2023.

Day 1 - January 18 2023
Think Locally, Source Globally: Are Your Products Region-Fixed or Trans-Continental?
Chairman to disucssion
3:30–5:00pm EST

Day 2 - January 19 2023
Storage and Preservation to Maintain High-Quality Raw Materials and Therapeutics
Presentation
1:30–3:00pm EST

Day 3 - January 20 2023
Disruptive and Novel Therapeutics for Oncology Indications
Presentation
9:00–10:30am EST

Glycostem is going to present at the Cell Therapy Manufacturing and Gene Therapy Congress 2022 in Amsterdam.

6 Dec 2022, 11:35 (CET)

Scaling to Commercial Scale: Cord Blood Stem Cell Derived NK Cells

- presented by John Veluchamy, Senior Development Scientist

6 Dec 2022, 15:00 (CET)

Quality by Design for Cell Therapy Manufacturing

- presented by Valters Stelmanis, Regulatory Specialist

Glycostem CDO Volker Huppert is going to participate and lead a discussion at European Immuno-Oncology Xchange 2022 roundtable meeting on 23^rd November 2022 in Zurich, Switzerland.

Topic: Cell Therapies going off-the-shelf: non-modified NK cells, CAR-NK cells, TCR-NK cells, combination therapies

Track: Next-Generation Therapies

Time: 16:15-17:15 (CET)

Glycostem CEO Troels Jordansen is attending the Jefferies London Healthcare Conference from 15^th to 16^th Nov 2022 in London. The Jefferies London Healthcare Conference is the largest healthcare-dedicated conference in Europe.